Featured Research

from universities, journals, and other organizations

Adipose dysfunction also linked to steatosis and necroinflammation, study finds

Date:
October 19, 2010
Source:
Wiley - Blackwell
Summary:
Researchers in Italy provide the evidence that a higher visceral adiposity index score -- a new index of adipose dysfunction -- has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).

Researchers at the University of Palermo in Italy provide the evidence that a higher visceral adiposity index score -- a new index of adipose dysfunction -- has a direct correlation with viral load and is independently associated with both steatosis and necroinflammatory activity in patients with genotype 1 chronic hepatitis C (G1 CHC).

Details of this study are available in the November issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

According to public health surveillance data gathered by the Centers for Disease Control and Prevention, nearly 75% of people with chronic hepatitis C virus infection in the U.S. have genotype 1, the hardest type to treat. Steatosis (fatty liver) and insulin resistance (IR), are frequent findings in patients with G1 CHC. Prior studies indicate that these metabolic features not only are independently associated with the severity of liver damage, but also are negative predictors of sustained virologic response (SVR) after standard antiviral therapy.

Visceral adipose tissue is believed to secrete a variety of substances that regulate metabolism, inflammation, and immunity, participating in the pathogenesis of cardiovascular disease, IR and diabetes. To determine whether visceral adiposity is directly associated with the metabolic factors that cause liver damage, a recent study introduced the visceral adiposity index (VAI) score, which uses both anthropometric (body mass index (BMI) and waist circumference) and metabolic (triglyceride and HDL) parameters to measure visceral fat mass, a key factor in metabolic alteration development, and the effect of visceral obesity on the histological features of liver disease. The VAI assesses fat distribution and function as well as cardiometabolic risk, and has been proposed as a surrogate marker of adipose tissue dysfunction.

In the current study, Salvatore Petta, M.D., and colleagues tested the VAI and its association with histological features and SVR in 236 patients with G1 CHC. Participants were evaluated by liver biopsy and anthropometric and metabolic measurements, including IR, the homeostasis model assessment (HOMA), and VAI by using waist circumference, BMI, triglycerides and HDL. All biopsies were scored for staging and grading, and graded for steatosis, which was considered moderate-severe if ≥30%. Patients were treated with the standard antiviral therapy of pegylated interferon plus ribavirin. The majority of study participants were in the overweight to obesity range, and nearly 25% were hypertensive. Diabetes was present in 11% of patients, and IR in 42.8%. Metabolic syndrome was diagnosed in 14.9% of patients. One patient in five had fibrosis ≥ 3 by Scheuer score, with a high prevalence of moderate/severe necroinflammation (grading 2-3). Half of the cases had histological evidence of steatosis, though of moderate/severe grade in only 40 cases (16.9%).

One hundred sixty-two patients completed the antiviral treatment program. SVR was achieved in 77 patients (47.5%). VAI score had a direct correlation with HCV viral load and was independently associated with higher HOMA score, higher HCV RNA levels, necroinflammatory activity, and steatosis, by multiple linear regression analysis. IR, higher VAI score, and fibrosis were linked to steatosis, suggesting adipose tissue may interfere with liver fatty accumulation not only by IR promotion, but also by exercising its well-known function as an endocrine organ able to modulate metabolic functions, including steatogenesis. Older age, high VAI score, and fibrosis were independently associated with moderate-severe necroinflammatory activity by logistic regression analysis.

"Our study found that moderate-severe necroinflammatory activity is independently associated not only with older age but also with VAI score," commented Dr. Petta. "To the best of our knowledge, we have provided the first evidence of an independent link between adipose dysfunction and liver inflammation in CHC." The authors indicate that the index may be able to reflect the ability of adipose tissue to generate proinflammatory mediators capable of participating in liver inflammatory response during HCV infection.

Dr. Petta concluded, "We suggest using VAI as an indicator of adipose-related liver damage, as predictor of liver disease progression, and as a new therapeutic outcome measure in the management of G1 CHC patients."


Story Source:

The above story is based on materials provided by Wiley - Blackwell. Note: Materials may be edited for content and length.


Journal Reference:

  1. Salvatore Petta, Marco Amato, Daniela Cabibi, Calogero Cammΰ, Vito Di Marco, Carla Giordano, Aldo Galluzzo, Antonio Craxμ. Visceral adiposity index is associated with histological findings and high viral load in patients with chronic hepatitis C due to genotype 1. Hepatology, 2010; DOI: 10.1002/hep.23859

Cite This Page:

Wiley - Blackwell. "Adipose dysfunction also linked to steatosis and necroinflammation, study finds." ScienceDaily. ScienceDaily, 19 October 2010. <www.sciencedaily.com/releases/2010/10/101019090910.htm>.
Wiley - Blackwell. (2010, October 19). Adipose dysfunction also linked to steatosis and necroinflammation, study finds. ScienceDaily. Retrieved August 22, 2014 from www.sciencedaily.com/releases/2010/10/101019090910.htm
Wiley - Blackwell. "Adipose dysfunction also linked to steatosis and necroinflammation, study finds." ScienceDaily. www.sciencedaily.com/releases/2010/10/101019090910.htm (accessed August 22, 2014).

Share This




More Health & Medicine News

Friday, August 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Drug Used To Treat 'Ebola's Cousin' Shows Promise

Newsy (Aug. 21, 2014) — An experimental drug used to treat Marburg virus in rhesus monkeys could give new insight into a similar treatment for Ebola. Video provided by Newsy
Powered by NewsLook.com
Cadavers, a Teen, and a Medical School Dream

Cadavers, a Teen, and a Medical School Dream

AP (Aug. 21, 2014) — Contains graphic content. He's only 17. But Johntrell Bowles has wanted to be a doctor from a young age, despite the odds against him. He was recently the youngest participant in a cadaver program at the Indiana University NW medical school. (Aug. 21) Video provided by AP
Powered by NewsLook.com
American Ebola Patients Released: What Cured Them?

American Ebola Patients Released: What Cured Them?

Newsy (Aug. 21, 2014) — It's unclear whether the American Ebola patients' recoveries can be attributed to an experimental drug or early detection and good medical care. Video provided by Newsy
Powered by NewsLook.com
Lost Brain Cells To Blame For Sleep Problems Among Seniors

Lost Brain Cells To Blame For Sleep Problems Among Seniors

Newsy (Aug. 21, 2014) — According to a new study, elderly people might have trouble sleeping because of the loss of a certain group of neurons in the brain. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins